Ranolazine is an effective anti-anginal agent shown to be effective in patients with diabetes and can also reduce the use of…
A recent randomized double-blinded reported that ranolazine reduced chest pain in diabetic patients with angina and deceased the use of sublingual (SL) nitroglycerin tablets.
The trial was 8 weeks in duration and patients were randomized to receive ranolazine or a placebo. Participants of this study had type-2 diabetes and experienced at least one episode of angina per week. The episodes of angina were recorded in an electronic diary by the patients. The results of this study showed that ranolazine was more effective at reducing angina and SL nitroglycerin use in patients that had poor glucose control.
Chief Investigator, Dr. Kosiborod concluded: "Ranolazine is an effective anti-anginal drug in patients with diabetes, and may also have a glucose-lowering effect. If the glucose-lowering action of ranolazine is confirmed in future studies, patients with diabetes and angina may derive a dual benefit from this drug."
Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus and Chronic Stable Angina. J Am Coll Cardiol, March 2013